Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CBT 101 - CHA Bio & Diostech

Next Previous
Search
Drug Profile

CBT 101 - CHA Bio & Diostech

Alternative Names: CBT 101 - CHA Bio & Diostech; CHANK-101

Latest Information Update: 31 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CHA Bio & Diostech
  • Class Antineoplastics; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glioblastoma
  • Phase I Solid tumours
  • Clinical Phase Unknown Ovarian cancer

Most Recent Events

  • 17 Mar 2025 CHA Bio & Diostech completes a phase-I/II trial in Glioblastoma (Recurrent) (Parenteral) before March 2025 (CHA Bio & Diostech pipeline, March 2025)
  • 12 Mar 2025 Clinical trials in Ovarian cancer (Parenteral) before March 2025 (CHA Bio & Diostech pipeline, March 2025)
  • 12 Mar 2025 Phase-I/II clinical trials in Glioblastoma (Recurrent) (Parenteral) before March 2025 (CHA Bio & Diostech pipeline, March 2025)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top